GleamWall
中文EN

ANIX Anixa Biosciences Inc

Pharmaceutical Preparations · Nasdaq · SEC CIK 715446 · Fiscal year ends 10/31

Financial factors as of 2026-07-31 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY6.6%
TTM EPS YoY5.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-66.8%
ROA-63.4%
ROIC (approx.)-61.6%
Asset turnover—

Leverage & solvency

Liabilities / assets12.4%
Debt / equity0.00x
Current ratio8.54x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.71x
Accruals ratio-18.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-10-31FY20242024-10-31
Income statement
Revenue—$210,000
R&D expense$5.07M$6.40M
SG&A expense$6.63M$7.43M
Operating income-$11.70M-$13.83M
Net income-$10.93M-$12.55M
EPS (basic)-0.34-0.39
EPS (diluted)-0.34-0.39
Weighted avg. shares (diluted)32,45431,898
Balance sheet
Cash & equivalents$1.24M$1.27M
Short-term investments$13.93M$18.65M
Receivables—$173,000
Current assets$15.89M$21.36M
Total assets$16.08M$21.59M
Current liabilities$1.97M$2.50M
Total liabilities$2.13M$2.70M
Shareholders' equity$15.16M$20.00M
Shares outstanding33.01M32.20M
Cash flow statement
Operating cash flow-$7.17M-$7.33M
Investing cash flow$4.87M$4.28M
Financing cash flow$2.28M$3.42M
Stock-based compensation$3.68M$4.42M
Share buybacks—$6,000

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.